-
the products youSC
IGFLUVACCINE
PRODUCTCOAGULATIO
ALBUMI LASMA PROTEIN/PLASMA PROTEIN FRACTI
IVIGHYPERIMMUNELOBULGLOBULINSVACCINES
IGIMHYPERIMMUNELOBULGLOBULINSVACCINES
CIG COA
PRO
when yo
TSON
TION
G
M
SC ALBUMI
IGI
VA
CCIN
ESHYPEGLO
RPROTALBU
N/P
PRO
24h
enterprises.com .FFF(800) 843-7477 | www om 102TCO 5
-
ACTURER
FFAMAN
U
om tampering or misis never in question frans th his
meTce.another distributor or sour
om the oducts frchase pr we only pur,At FFFchasingurP
8Critical S
shandling.oducts our pr he integrity of
om never frr – e manufactur
Steps
and supported with bace variatioaturto temper
ansport e and tre storWagetorS
ators in the event oup gener ck molled,e contraturemperT
ons.
otein compounds th viable pr
s. power los ofed 24/7, monitor
e sensitive at ar
ate efrigerragingpack
Specia
oducts.ed prozen and ecautions for fra prxtr taking eg,
agingackalty P
oducts in challenging pr
active AlloInter
educes Ret conditions. g mark
ocation
potential for
CONT
Hyperim Immune
t oagulaCCustome
ce esourR
ENTS
. . . . . . . . . . . . . . . . . . . .mune Globulins.. . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . Globulins
.. . . . . . . . . . . . . . . . . . . . . . . .oducts rtion
P... . . . . . . . . . . . . . . . . . . . . . . . . . . .ter
Suppor
... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . .es
Onc10... ... . . . . . . . . . . . . . . . . . .8–9... . . . . .
. . . . . . . . . . . . . .6–8... . . . . . . . . . . . . . . . . .
. .
5.. . . . . . . . . . . . . . . . . . . . . . . . .4.. . . . . .
. . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.cology
... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
14–15... . . . . . . . . . . . . . . . . . . . . . . . . . .
1413... . . . . . . . . . . . . . . . . . . . . . . . . . . .
.12... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. .11... . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
yp
11... . . . . . . . . . . . . . .
gy
15... . . . . . . . . . . . . . . . . .
http://www.fffenterprises.com/company/guaranteed-channel-integrity.html
-
seco to d add
e WDe
nChannel ITo Guaran
ondary distribution channel.om enterin oducts frevent pr do
everything in our power to pr
It is our commitment ceptions.xe no ee makWs on the license.esdr
and only sued license, deliver only to facilities with a
state-is
elivery
™yntegrit nteed
ng a itment
y to the
allows time-s Monitoring a
e pr sensitive delivery to ensura eme wextr and adjusting for
e
.oduct integrity rather conditions
chased pharmaceuticals puree of
to e
omer information,
e asily verify online the pedigr
. drug we supplyfor every vial of
matched to custo ,oduct lot numberach pre
less safety record.strated by our flawis demontical supply
chainarmaceuent to a secure phOur commitm
Since 1988S er 27 counterfeit-free yearsOv
http://www.fffenterprises.com/company/guaranteed-channel-integrity.html
-
Resourc
m
pp y
in T
Subscribe and view our online
ends Quarterly MagrTBioSupply
etplace.marknformation for the biopharmaceutical
ce for newhe definitive sourT
ces
view our online
azine asonal Flu
omplimentary posters in English, maceutical
ends and tr ws,
accination cli
Se
nd Mandarin C
der or download online
oster u P
Or inics.omote flu n to help plan and pr Spanish ry posters in
English,
e
pg R
Quarterly
Subscribe and view our online
IG Living! Magazine
ovidersprglobulin patients and their he
sful livin ces for succesesourR
T.BSedition at www
.com
w our online e althcar e
ng for immune
Flu
en
i ti
ac Myths & F
fhighlighting prDispelling the myths about the dise
.FFFt www
terprises.com
d li t
eochurts Br
Oevention and the benefits g pr
ase and he myths about the dise
e
prAw
p.IGLiving.com
oviding insight into the comple
teeNewsletends rBioSupply T
rd-winning bimonthly war
edition at www Subscribe and view our online oviders.pr
m
xities of
er
completer y eNewslet
w our online
oe
ent
individual customer gr
ommunication AlertseC
fommunic C
.FFFwww vaccinatioof
terprises.com
oups and patient
tion Alerts
al customer gred to meet the needs cations tailor
der online at Or on.
ence Cha eferRs complim FFF’
Su th p
• Immune Glob
ence Charts
.F
asonal Infl • See highly
eferoduct RrP
rts aroductr entary P
ubscribe online at wwwhe specialty pharmaceuti
g g
enterprises.com
bulinaccine V uenza
FFFetplace. cals mark
p
wo
eimburseme
ent.FFFwwwganizationr
IVIG R
ind F
alculator
terprises.com
ent
Subscribe online atns.p p g
ent C
d the curr
d Or
ative pcomparvalued educati
ence Cha eferR
actor VIIIF• Anti-Inhibitor •
• Hyperimmun Immune Glob
enterprises.FFFer charts online at www
oduct information. rces foresour ional r
e highly rts ar
VIIa & IXactor r F ne Globulin bulin
s.com
at weim r
enterprises.com.FFF wwwates for IVIG mbursement r
O ORDER TO
ax (800) 418- (800) 843-7477 | F
enterprises.com | www.FFF -4333 | www
fenterprises.comfffenterprises.com.fffaccine.com |
biosupply.MyFluVVaccine.com | biosupplym | www4
http://www.bstquarterly.com/http://www.igliving.com/http://www.fffenterprises.com/resources/biosupply-trends-enewsletter.htmlhttp://www.fffenterprises.com/resources/reference-charts.htmlhttp://www.fffenterprises.com/resources/seasonal-flu-posters.htmlhttp://www.fffenterprises.com/resources/flu-myths-facts-brochure.htmlhttp://www.fffenterprises.com/resources/ecommunications.htmlhttp://www.fffenterprises.com/resources/ivig-reimbursement-calculator.aspxhttp://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
Custom
From our in house teams o
e to Suppoe HerArow! CustomeWOur
upporter S
ou.Yoofessionals r P™ear C
of cu
Yt rrter C
r
From our in-house teams of curepresentatives, advisors and
managers, there is always a rededicated expert to take care
Emergency ordering and shippin
On-call pharmacist™ fo
Lot-Track™
BioSupply™ online ordering and
Specialty publications for current and inventory news
Expert advisors
Patient advocates
24h
f
(800) 843-7477FFF Enterprises.
ovidevery drug prdosing questions about
odanswer your prtise xperhave the e
Our on-call pharm
(800) 843-7477outcomes.
tient oving paimpre and fective carcost-efffective car
,apyy,neous infusion theravenous and subcuta- intr
about the principles ofwill answer your questions Our infusion
specialists
Advisor LinePharmacy
Advisor LineInfusion
Nationwide, robust sales force of
eimbursement Our rmacists Advisor Line
eimbursementR
(800) 843-7477eimbursement.r
biopharmaceutical ofxities the compleough and guide you thr
esolve your questions rady to ee rspecialists ar
ed by about uct or e to
fenterprises.comfffenterprises.com.fffaccine.com |
biosupply.MyFluVVaccine.com | biosupplym | www
enterprises.com | www.FFFax (800) 418-4333 | www (800) 843-7477
| FO ORDER TO 5
http://www.fffenterprises.com/site/company-contacts.htmlhttp://www.fffenterprises.com/site/company-contacts.htmlhttp://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
Product Size Manufacturer NDC# Code*
ANTI-INHIBITOR (HUMAN-PLASMA DERIVED)
FEIBA NF 500 IU VIAL W/BAXJECT II BAXALTA 64193-0423-02 J7198
1000 IU VIAL W/BAXJECT II 64193-0424-02 J7198 2500 IU VIAL
W/BAXJECT II 64193-0425-02 J7198
FACTOR VIIa (RECOMBINANT)
NOVOSEVEN RT 1000 MCG VIAL NOVO NORDISK 00169-7201-01 J7189 WITH
MIXPRO 2000 MCG VIAL 00169-7202-01 J7189 5000 MCG VIAL
00169-7205-01 J7189 8000 MCG VIAL 00169-7208-01 J7189
FACTOR VIII (HUMAN–PLASMA DERIVED)
KOATE DVI 250 IU VIAL KEDRION 76125-0250-20 J7190 500 IU VIAL
76125-0500-30 J7190 1000 IU VIAL 76125-0672-50 J7190
VON WILLEBRAND FACTOR / FACTOR VIII COMPLEX (HUMAN-PLASMA
DERIVED)
ALPHANATE 250 IU VIAL+ GRIFOLS 68516-4601-01 J7186 500 IU VIAL+
68516-4602-01 J7186 1000 IU VIAL+ 68516-4603-02 J7186 1500 IU VIAL+
68516-4604-02 J7186 HUMATE-P 500 RCOF+ VIAL CSL BEHRING
63833-0615-02 J7187 1000 RCOF+ VIAL 63833-0616-02 J7187 2000 RCOF+
VIAL 63833-0617-02 J7187
WILATE 500 IU VIAL+ OCTAPHARMA 67467-0182-01 J7183 1000 IU VIAL+
67467-0182-02 J7183
FACTOR VIII (RECOMBINANT)
ADVATE 2 ML 250 IU VIAL BAXALTA 00944-2921-02 J7192 500 IU VIAL
00944-2922-02 J7192 1000 IU VIAL 00944-2923-02 J7192 1500 IU VIAL
00944-2924-02 J7192
ADVATE 5 ML 2000 IU VIAL BAXALTA 00944-2964-10 J7192 3000 IU
VIAL 00944-2965-10 J7192 4000 IU VIAL 00944-2948-10 J7192
ELOCTATE 250 IU VIAL BIOGEN IDEC 64406-0801-01 J7199 500 IU VIAL
64406-0802-01 J7199 750 IU VIAL 64406-0803-01 J7199 1000 IU VIAL
64406-0804-01 J7199 1500 IU VIAL 64406-0805-01 J7199 2000 IU VIAL
64406-0806-01 J7199 3000 IU VIAL 64406-0807-01 J7199
HELIXATE FS 250 IU VIAL CSL BEHRING 00053-8131-02 J7192 500 IU
VIAL 00053-8132-02 J7192 1000 IU VIAL 00053-8133-02 J7192 2000 IU
VIAL 00053-8134-02 J7192 3000 IU VIAL 00053-8135-02 J7192
KOGENATE FS 250 IU VIAL W/BIOSET BAYER 00026-3792-20 J7192 500
IU VIAL W/BIOSET 00026-3793-30 J7192 1000 IU VIAL W/BIOSET
00026-3795-50 J7192 2000 IU VIAL W/BIOSET 00026-3796-60 J7192
Coagulation Products
Continued*All codes should be verified between the provider and
the payer.+Call (800) 843-7477 or check ordering screen for RCo
values.
VIPc
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc Verified Inventory Program–Consignment eligible. Public
Health Services 340B pricing available.340B
6
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
Continued
Product Size Manufacturer NDC# Code*
FACTOR VIII (RECOMBINANT) CONTINUED KOGENATE FS VIAL ADAPTER 250
IU VIAL W/VIAL ADAPTER BAYER 00026-3782-25 J7192 500 IU VIAL W/VIAL
ADAPTER 00026-3783-35 J7192 1000 IU VIAL W/VIAL ADAPTER
00026-3785-55 J7192 2000 IU VIAL W/VIAL ADAPTER 00026-3786-65
J7192
NOVOEIGHT 250 IU VIAL NOVO NORDISK 00169-7825-01 J7182 500 IU
VIAL 00169-7850-01 J7182 1500 IU VIAL 00169-7815-01 J7182 2000 IU
VIAL 00169-7820-01 J7182 3000 IU VIAL 00169-7830-01 J7182
RECOMBINATE 250 IU VIAL BAXALTA 00944-2841-10 J7192 500 IU VIAL
00944-2842-10 J7192 1000 IU VIAL 00944-2843-10 J7192 1500 IU VIAL
00944-2844-10 J7192 2000 IU VIAL 00944-2845-10 J7192
XYNTHA 250 IU VIAL PFIZER 58394-0012-01 J7185 500 IU VIAL
58394-0013-01 J7185 1000 IU VIAL 58394-0014-01 J7185 2000 IU VIAL
58394-0015-01 J7185 3000 IU VIAL 58394-0016-03 J7185
XYNTHA SOLOFUSE 250 IU/4ML DCS PFIZER 58394-0022-03 J7185 500
IU/4ML DCS 58394-0023-03 J7185 1000 IU/4ML DCS 58394-0024-03 J7185
2000 IU/4ML DCS 58394-0025-03 J7185
FACTOR VIII (MONOCLONAL PURIFIED)
HEMOFIL M 250 IU VIAL BAXALTA 00944-3940-02 J7190 500 IU VIAL
00944-3942-02 J7190 1000 IU VIAL 00944-3944-02 J7190 1500 IU VIAL
09444-3946-02 J7190
MONOCLATE-P 1000 IU VIAL CSL BEHRING 00053-7656-04 J7190 1500 IU
VIAL 00053-7656-05 J7190
FACTOR IX (HUMAN–PLASMA DERIVED)
ALPHANINE SD 500 IU VIAL GRIFOLS 68516-3601-02 J7193 1000 IU
VIAL 68516-3602-02 J7193 1500 IU VIAL 68516-3603-03 J7193
BEBULIN 500 IU VIAL BAXALTA 06419-3445-02 J7194
FACTOR IX (MONOCLONAL PURIFIED)
MONONINE 1000 IU VIAL CSL BEHRING 00053-6223-02 J7193
FACTOR IX (RECOMBINANT)
ALPROLIX 500 IU VIAL BIOGEN IDEC 64406-0911-01 J7199 1000 IU
VIAL 64406-0922-01 J7199 2000 IU VIAL 64406-0933-01 J7199 3000 IU
VIAL 64406-0944-01 J7199
BENEFIX RT 250 IU VIAL PFIZER 58394-0633-03 J7195 500 IU VIAL
58394-0634-03 J7195 1000 IU VIAL 58394-0635-03 J7195 2000 IU VIAL
58394-0636-03 J7195 3000 IU VIAL 58394-0637-03 J7195
RIXUBIS 250 IU VIAL BAXALTA 00944-3026-02 J7195 500 IU VIAL
00944-3028-02 J7195 1000 IU VIAL 00944-3030-02 J7195 2000 IU VIAL
00944-3032-02 J7195 3000 IU VIAL 00944-3034-02 J7195
Coagulation Products
*All codes should be verified between the provider and the
payer.
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc340B
VIPc340B
VIPc340B
VIPc Verified Inventory Program–Consignment eligible. Public
Health Services 340B pricing available.340B
7
COAGUALATIONIM
MUNE
GLOBULINSHYPERIM
MUNES
INFLUENZA VACCINES& ANCILLARIES
OTHERVACCINES
ALBUMIN / PLASM
APROTEIN FRACTION
SPECIALTY& ONCOLOGY
GENERIC INJECTABLES& SURGICAL SEALANTS
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
Product Size Manufacturer NDC# Code*
IMMUNE GLOBULINS SUBCUTANEOUS (SCIG)
HIZENTRA 1 GM VIAL CSL BEHRING 44206-0451-01 J1559 2 GM VIAL
44206-0452-02 J1559 4 GM VIAL 44206-0454-04 J1559 10 GM VIAL
44206-0455-10 J1559
HYQVIA 2.5 GM VIAL BAXALTA 00944-2510-02 5 GM VIAL 00944-2511-02
10 GM VIAL 00944-2512-02 20 GM VIAL 00944-2513-02 30 GM VIAL
00944-2514-02
GAMUNEX-C 1 GM VIAL GRIFOLS 13533-0800-12 J1561 2.5 GM VIAL
13533-0800-15 J1561 5 GM VIAL 13533-0800-20 J1561 10 GM VIAL
13533-0800-71 J1561 20 GM VIAL 13533-0800-24 J1561 40 GM VIAL
13533-0800-40 J1561
GAMMAGARD LIQUID 1 GM VIAL BAXALTA 00944-2700-02 J1569 2.5 GM
VIAL 00944-2700-03 J1569 5 GM VIAL 00944-2700-04 J1569 10 GM VIAL
00944-2700-05 J1569 20 GM VIAL 00944-2700-06 J1569 30 GM VIAL
00944-2700-07 J1569
GAMMAKED 1 GM VIAL KEDRION 76125-0900-01 J1561 2.5 GM VIAL
76125-0900-25 J1561 5 GM VIAL 76125-0900-50 J1561 10 GM VIAL
76125-0900-10 J1561 20 GM VIAL 76125-0900-20 J1561
OTHER COAGULATION PRODUCTS
KCENTRA 500 IU VIAL CSL BEHRING 63833-0386-02 J3590 1000 IU VIAL
63833-0387-02 J3590
PROFILNINE SD 500 IU VIAL GRIFOLS 68516-3201-01 J7194 1000 IU
VIAL 68516-3202-02 J7194 1500 IU VIAL 68516-3203-02 J7194
RIASTAP 1000 MG VIAL CSL BEHRING 63833-0891-51 J1680
STIMATE NASAL SPRAY 1.5 ML CSL BEHRING 00053-6871-00 J3490
Immune Globulins Subcutaneous (SCIG)
Product Size Manufacturer NDC# Code*
IMMUNE GLOBULIN INTRAMUSCULAR (IGIM) GAMASTAN S/D 2 ML VIAL
GRIFOLS 13533-0635-04 J1460 10 ML VIAL 13533-0635-12 J1460
Immune Globulin Intramuscular (IGIM)
*All codes should be verified between the provider and the
payer.
**Call Baxalta Reimbursement at (888) 229-8379 for the most
up-to-date billing code.
J3490 or J3590** J3490 or J3590** J3490 or J3590** J3490 or
J3590** J3490 or J3590**
Product Size Manufacturer NDC# Code*
Coagulation Products (CONTINUED)
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc340B
VIPc340B
VIPc Verified Inventory Program–Consignment eligible. Public
Health Services 340B pricing available.340B
8
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
9TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
Product Size Manufacturer NDC# Code*
IMMUNE GLOBULINS (HUMAN) LYOPHILIZED
CARIMUNE NF 6 GM VIAL CSL BEHRING 44206-0417-06 J1566 12 GM VIAL
44206-0418-12 J1566
GAMMAGARD S/D 5 GM VIAL BAXALTA 00944-2656-03 J1566(IGA
-
Product Size Manufacturer NDC# Code*
ANTI-THYMOCYTE GLOBULIN
THYMOGLOBULIN 25 MG VIAL SANOFI AVENTIS 58468-0080-01 J7511
BOTULISM IGIV (HUMAN) (BIG-IV)
BABYBIG 100 MG VIAL CALIFORNIA DEPT. OF HEALTH 68403-1100-06
—
CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)
CYTOGAM 2.5 GM VIAL CSL BEHRING 44206-0532-11 J0850
HEPATITIS B IMMUNE GLOBULIN
HEPAGAM B 1 ML VIAL EMERGENT BIOSOLUTIONS 53270-0052-01 J1571 or
J1573 5 ML VIAL 53270-0051-01 J1571 or J1573
HYPERHEP B S/D 0.5 ML SYRINGE GRIFOLS 13533-0636-03 90371 1 ML
SYRINGE 13533-0636-02 90371 5 ML VIAL 13533-0636-05 90371
NABI-HB 1 ML SDV BIOTEST PHARMACEUTICALS 59730-4202-01 90371 5
ML SDV 59730-4203-01 90371
RABIES IMMUNE GLOBULIN
HYPERRAB S/D 2 ML 150 IU/ML VIAL GRIFOLS 13533-0618-02 90375 10
ML 150 IU/ML VIAL 13533-0618-10 90375
RHO(D) IMMUNE GLOBULIN
HYPERRHO S/D 50 MCG/0.17 ML SYRINGE GRIFOLS 13533-0661-06 J2788
300 MCG 1 ML SYRINGE 13533-0631-02 J2790
MICRHOGAM 50 MCG 1 ML SYRINGE KEDRION 00562-7806-01 J2788 50 MCG
1 ML SYRINGE/5-PK 00562-7806-05 J2788 50 MCG 1 ML SYRINGE/25-PK
00562-7806-25 J2788
RHOGAM 300 MCG 1 ML SYRINGE KEDRION 00562-7805-01 J2790 300 MCG
1 ML SYRINGE/5-PK 00562-7805-05 J2790 300 MCG 1 ML SYRINGE/25-PK
00562-7805-25 J2790
RHOPHYLAC 300 MCG SYRINGE CSL BEHRING 44206-0300-01 J2791 300
MCG SYRINGE/10-PK 44206-0300-10 J2791
WINRHO SDF 1500 IU 300 MCG VIAL EMERGENT BIOSOLUTIONS
53270-3300-01 J2792 2500 IU 500 MCG VIAL 53270-3500-01 J2792 5000
IU 1000 MCG VIAL 53270-3100-01 J2792 15,000 IU 3000 MCG VIAL
53270-3000-01 J2792
TETANUS IMMUNE GLOBULIN
HYPERTET S/D 250 UNIT SYRINGE GRIFOLS 13533-0634-02 J1670
VARICELLA ZOSTER IMMUNE GLOBULIN
VARIZIG LIQUID 125 UNIT VIAL EMERGENT BIOSOLUTIONS 53270-0126-02
90396
Hyperimmune Globulins
*All codes should be verified between the provider and the
payer.
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
VIPc
VIPc
VIPc
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc340B
VIPc Verified Inventory Program–Consignment eligible. Public
Health Services 340B pricing available.340B
VIPc340B
10
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
11
Product Size Manufacturer NDC# Code*
INFLUENZA VACCINES 2015-16 FLUVIRIN 5 ML 10 DS VIAL NOVARTIS
66521-0118-10 90658/Q2037 0.5 ML PFS 66521-0118-02 90656 FLUCELVAX
0.5 ML PFS NOVARTIS 62577-0614-01 90661FLUZONE 5 ML 10 DS VIAL
SANOFI PASTEUR 49281-0396-15 90657/90658/Q2038FLUZONE QUADRIVALENT
5 ML 10 DS VIAL SANOFI PASTEUR 49281-0623-15 90687/90688 0.25 ML
PFS 49281-0515-25 90685 0.5 ML PFS 49281-0415-50 90686 0.5 ML SDV
49281-0415-10 90686FLUZONE HIGH DOSE 0.5 ML PFS SANOFI PASTEUR
49281-0397-65 90662FLUZONE INTRADERMAL QUADRIVALENT 0.1 ML PFS
SANOFI PASTEUR 49281-0708-40 90630AFLURIA 5 ML 10 DS VIAL BIOCSL
33332-0115-10 90658/Q2035 0.5 ML PFS 33332-0015-01 90656FLULAVAL
QUADRIVALENT 5 ML 10 DS VIAL GSK 19515-0898-11 90688FLUARIX
QUADRIVALENT 0.5 ML PFS GSK 58160-0903-52 90686FLUMIST QUADRIVALENT
0.2 ML INTRANASAL SPRAYER MEDIMMUNE 66019-0302-10 90672FLUBLOK 0.5
ML SDV PROTEIN SCIENCES 42874-0015-10 90673ANTIVIRALS RELENZA
ROTADISK 5 MG GSK 00173-0681-01 —TAMIFLU 75 MG CAP 10-PK GENENTECH
00004-0800-85 J8499TAMIFLU ORAL SUSP 6 MG/ML GENENTECH
00004-0822-05 J8499
Product Description Manufacturer
PHARMAJET® NEEDLE-FREE INJECTION PRODUCTS (AVAILABLE ONLY FOR
AFLURIA 5 ML 10 DS VIAL)
INJECTOR STARTER KIT SUPPLIES 500 FLU SHOTS AND INCLUDES:
PHARMAJET - (1) PHARMAJET INJECTOR - (5) BOXES OF NEEDLE-FREE
SYRINGES – 100/BOX - (1) BOX OF VIAL ADAPTERS – 100/BOX - (1) RESET
STATION - (1) PRACTICE KIT
NEEDLE-FREE SYRINGES 100/BOX PHARMAJETVIAL ADAPTERS 100/BOX
PHARMAJETPHARMAJET INJECTOR SPRING-OPERATED INJECTOR, REQUIRING
PHARMAJET NO EXTERNAL POWER SOURCE
RESET STATION PREPARES THE INJECTOR FOR VACCINE ADMINISTRATION
PHARMAJET
DISPOSABLE CONTAINERS SHARPS RECOVERY SYSTEM® 1-QUART,
1.5-QUART, 1-GALLON SHARPS COMPLIANCE 2-GALLON, 3-GALLON, 20-GALLON
SHARPS RECOVERY SYSTEM® 5-GALLON SHARPS COMPLIANCEFOR USE WITH
NON-SHARPS BIOHAZARD WASTE ONLY
*All codes should be verified between the provider and the
payer.
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com 11
COAGUALATIONIM
MUNE
GLOBULINSHYPERIM
MUNES
INFLUENZA VACCINES& ANCILLARIES
OTHERVACCINES
ALBUMIN / PLASM
APROTEIN FRACTION
SPECIALTY& ONCOLOGY
GENERIC INJECTABLES& SURGICAL SEALANTS
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
A 250 ML KEDRION 76125-0785-25 P9045 250 ML 76125-0790-25
P9045
A 250 ML CSL BEHRING 00053-7670-31 P9045 500 ML 00053-7670-32
P9045
A 50 ML CSL BEHRING 00053-7680-32 P9047 100 ML 00053-7680-33
P9047
A 250 ML CSL BEHRING 44206-0310-25 P9045 500 ML 44206-0310-50
P9045
A 50 ML CSL BEHRING 44206-0251-05 P9047 100 ML 44206-0251-10
P9047
A 250 ML GRIFOLS 68516-5214-01 P9045 500 ML 68516-5214-02
P9045
A 50 ML GRIFOLS 68516-5216-01 P9047 100 ML 68516-5216-02
P9047
A 250 ML OCTAPHARMA 67467-0623-02 P9045 250 ML 68209-0623-02
P9045 500 ML 68209-0623-03 P9045 500 ML 67467-0623-03 P9045
A 50 ML OCTAPHARMA 67467-0643-01 P9047 50 ML 68209-0643-01 P9047
100 ML 67467-0643-02 P9047 100 ML 68209-0643-02 P9047
B 500 ML BAXALTA 00944-0491-02 P9045
B 20 ML BAXALTA 00944-0490-01 P9046 50 ML 00944-0490-02
P9047
F 250 ML BAXALTA 00944-0495-05 P9047
F 50 ML BAXALTA 00944-0493-01 P9047 100 ML 00944-0493-02
P9047
K 50 ML KEDRION 76179-0025-01 P9047 100 ML 76179-0025-04
P9047
P 50 ML GRIFOLS 13533-0685-20 P9041 250 ML 13533-0685-25
P9045
P 20 ML GRIFOLS 13533-0684-16 P9046 50 ML 13533-0684-20 P9047
100 ML 13533-0684-71 —
P 50 ML GRIFOLS 13533-0690-02 — 250 ML 13533-0690-25 —
P 20 ML GRIFOLS 13533-0692-16 — 50 ML 13533-0692-20 — 100 ML
13533-0692-71 —
P 50 ML PPF GRIFOLS 13533-0613-20 P9043 250 ML PPF 13533-0613-25
P9043
| biosupply.fffenterprises.com
P
12
Product Size Manufacturer NDC# Code*
OTHER VACCINES
ACTHIB 10 MCG W/DILUENT SANOFI PASTEUR 49281-0545-05 90648ADACEL
(TDAP) 5 PFS/BX SANOFI PASTEUR 49281-0400-15 90715 10 SDV/BX
49281-0400-10 90715DAPTACEL 10 SDV/BX SANOFI PASTEUR 49281-0286-10
90700DIPHTHERIA AND TETANUS TOXOID 10 SDV PF PEDS SANOFI PASTEUR
49281-0225-10 90714GARDASIL HPV 10 - 0.5 ML SDV MERCK 00006-4045-41
90649 0.5 ML VIAL 00006-4045-00 90649GARDASIL 9 HPV 10 - 0.5 ML SDV
MERCK 00006-4119-03 90651 10 - 0.5 ML PFS 00006-4121-02 90651IMOVAX
IM 1 SDV W/DILUENT SANOFI PASTEUR 49281-0250-51 90675IPOL POLIO
VIRUS 5 ML MDV SANOFI PASTEUR 49281-0860-10 90713MENACTRA SDV/5-PK
SANOFI PASTEUR 49281-0589-05 90734MENOMUNE SDV SANOFI PASTEUR
49281-0489-01 90733MMR II MEASLES MUMPS 0.5 ML SDV/10-PK MERCK
00006-4681-00 90707PEDVAX HIB 0.5 ML SDV/10-PK MERCK 00006-4897-00
90647PENTACEL SDV/5-PK SANOFI PASTEUR 49281-0510-05 90698PNEUMOVAX
23 0.5 ML SDV/10-PK MERCK 00006-4943-00 90732 2.5 ML VIAL
00006-4739-00 90732PREVNAR 13 PFS/10-PK PFIZER 00005-1971-02
90670PROQUAD 0.5 ML SDV/10-PK MERCK 00006-4999-00 90710RECOMBIVAX
HB ADULT 10 MCG/SDV MERCK 00006-4995-00 90746 10 MCG VIAL/10-PK
00006-4995-41 90743/90746 10 MCG PFS/6-PK 00006-4094-09
90743/90746RECOMBIVAX HB PED/ADOLESC 5 MCG/6-PK PFS MERCK
00006-4093-09 90744 5 MCG/0.5 ML 10-PK 00006-4981-00
90744RECOMBIVAX HB DIALYSIS 40 MCG SDV MERCK 00006-4992-00
90740/90747ROTATEQ ROTAVIRUS 2 ML TUBES/10-PK MERCK 00006-4047-41
90680 2 ML TUBES/25-PK 00006-4047-20 90680 TENIVAC 10 SDV/BX SANOFI
PASTEUR 49281-0215-10 90714 10 PFS/BX 49281-0215-15 90714TICE BCG
50 MG SDV MERCK 00052-0602-02 TBDTRUMENBA 0.5 ML SDV PF/5-PK PFIZER
00005-0100-05 90621 0.5 ML SDV PF/10-PK 00005-0100-10 90621TUBERSOL
1 ML VIAL 10 TEST SANOFI PASTEUR 49281-0752-21 86580 5 ML VIAL 50
TEST 49281-0752-22 86580TYPHIM VI TYPHOID 10 ML MDV SANOFI PASTEUR
49281-0790-20 90691 0.5 ML/PFS 49281-0790-51 90691VAQTA 50 U/1 ML
PFS/6-PK MERCK 00006-4096-09 90632 25 U/1 ML PFS/6-PK 00006-4095-09
90633 25 U/0.5 ML SDV/10-PK 00006-4831-41 90633VARIVAX 0.5 ML
SDV/10-PK MERCK 00006-4827-00 90716VIVOTIF BLISTER PK OF 4 CAPSULES
PAXVAX 58337-0003-01 90690ZOSTAVAX SDV/10-PK MERCK 00006-4963-41
90736 SDV 00006-4963-00 90736
Other Vaccines
*All codes should be verified between the provider and the
payer.
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
VIPc Verified Inventory Program–Consignment eligible.
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
VIPc
12
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
13
Product Size Manufacturer NDC# Code*
ALBUMIN / PLASMA PROTEIN FRACTION
ALBUKED 5% 250 ML KEDRION 76125-0785-25 P9045 250 ML
76125-0790-25 P9045
ALBUMINAR 5% 250 ML CSL BEHRING 00053-7670-31 P9045 500 ML
00053-7670-32 P9045
ALBUMINAR 25% 50 ML CSL BEHRING 00053-7680-32 P9047 100 ML
00053-7680-33 P9047
ALBURX 5% 250 ML CSL BEHRING 44206-0310-25 P9045 500 ML
44206-0310-50 P9045
ALBURX 25% 50 ML CSL BEHRING 44206-0251-05 P9047 100 ML
44206-0251-10 P9047
ALBUTEIN 5% 250 ML GRIFOLS 68516-5214-01 P9045 500 ML
68516-5214-02 P9045
ALBUTEIN 25% 50 ML GRIFOLS 68516-5216-01 P9047 100 ML
68516-5216-02 P9047
ALBUMIN 5% 250 ML OCTAPHARMA 67467-0623-02 P9045 250 ML
68209-0623-02 P9045 500 ML 68209-0623-03 P9045 500 ML 67467-0623-03
P9045
ALBUMIN 25% 50 ML OCTAPHARMA 67467-0643-01 P9047 50 ML
68209-0643-01 P9047 100 ML 67467-0643-02 P9047 100 ML 68209-0643-02
P9047
BUMINATE 5% 500 ML BAXALTA 00944-0491-02 P9045
BUMINATE 25% 20 ML BAXALTA 00944-0490-01 P9046 50 ML
00944-0490-02 P9047
FLEXBUMIN 5% 250 ML BAXALTA 00944-0495-05 P9047
FLEXBUMIN 25% 50 ML BAXALTA 00944-0493-01 P9047 100 ML
00944-0493-02 P9047
KEDBUMIN 25% 50 ML KEDRION 76179-0025-01 P9047 100 ML
76179-0025-04 P9047
PLASBUMIN 5% 50 ML GRIFOLS 13533-0685-20 P9041 250 ML
13533-0685-25 P9045
PLASBUMIN 25% 20 ML GRIFOLS 13533-0684-16 P9046 50 ML
13533-0684-20 P9047 100 ML 13533-0684-71 —
PLASBUMIN AFP 5% 50 ML GRIFOLS 13533-0690-02 — 250 ML
13533-0690-25 —
PLASBUMIN AFP 25% 20 ML GRIFOLS 13533-0692-16 — 50 ML
13533-0692-20 — 100 ML 13533-0692-71 —
PLASMANATE 5% (PPF) 50 ML PPF GRIFOLS 13533-0613-20 P9043 250 ML
PPF 13533-0613-25 P9043
Albumin / Plasma Protein Fraction
*All codes should be verified between the provider and the
payer.
*All codes should be verified between the provider and the
payer.TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
Public Health Services 340B pricing available.340B
340B
340B
340B
340B
340B
340B
340B
340B
340B
340B
340B
13
COAGUALATIONIM
MUNE
GLOBULINSHYPERIM
MUNES
INFLUENZA VACCINES& ANCILLARIES
OTHERVACCINES
ALBUMIN / PLASM
APROTEIN FRACTION
SPECIALTY& ONCOLOGY
GENERIC INJECTABLES& SURGICAL SEALANTS
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
*All codes should be verified between the provider and the
payer.
Product Size Manufacturer NDC# Code*
ONCOLOGY (GENERICS)CLOLAR 20 MG/ML VIAL SANOFI AVENTIS
58468-0100-01 J9027GEMCITABINE** 200 MG SUN PHARMA 47335-0153-40
J9201 1 GM 47335-0154-40 J9201ONDANSETRON INJECTION** 4 MG/2 ML
25-PK HERITAGE PHARMA 23155-0196-43 J2405OXALIPLATIN** 50 MG/10 ML
SDV SUN PHARMA 47335-0046-40 J9263 100 MG/20 ML 47335-0047-40
J9263ZALTRAP 100 MG/4 ML VIAL SANOFI AVENTIS 00024-5840-01 J9400
200 MG/ 8 ML VIAL 00024-5841-01 J9400ZOLINZA 100 MG ORAL CAPSULE
MERCK 00006-0568-40 J8999
Oncology
Continued
Product Size Manufacturer NDC# Code*
SPECIALTY BIOPHARMACEUTICALS AND PHARMACEUTICALSACTIVASE 50
MG/50 ML VIAL GENENTECH 50242-0044-13 J2997 100 MG/100 ML VIAL
50242-0085-27 J2997
AMPICILLIN/SULBACTAM** 3 GM 10/PK AURO MEDICS 55150-0117-20
J0295ATRYN 525 IU VIAL REVO BIOLOGICS 42976-0121-01 J7196 1750 IU
VIAL 42976-0121-02 J7196BERINERT 500 IU VIAL CSL BEHRING
63833-0825-02 J0597CROFAB 2 VIAL PK BTG INTERNATIONAL 50633-0110-12
J0840CUBICIN 500 MG SDV/10-PK MERCK 67919-0011-01 J0878DIGIFAB 40
MG VIAL BTG INTERNATIONAL 50633-0120-11 J1162FOLLISTIM AQ 75 IU SDV
MERCK 00052-0308-02 J3490 300 IU CARTRIDGE 00052-0313-01 J3490 600
IU CARTRIDGE 00052-0316-01 J3490 900 IU CARTRIDGE 00052-0326-01
J3490FUROSEMIDE** 20 MG/2 ML 25-PK HERITAGE PHARMA 23155-0521-41
J1940 40 MG/4 ML 25-PK 23155-0521-42 J1940 100 MG/10 ML 25-PK
23155-0521-44 J1940GANIRELIX ACETATE 250 MCG/0.5 ML PFS MERCK
00052-0301-51 S0132HEMABATE 1 ML VIAL/10-PK PFIZER 00009-0856-08
J3490INTEGRILIN 75 MG/ML 100 ML VIAL MERCK 00085-1136-01 J1327 2
MG/ML 10 ML VIAL 00085-1177-01 J1327 2 MG/ML 100 ML VIAL
00085-1177-02 J1327MEROPENEM** 20 ML/500 MG 25/PK FRESENIUS KABI
63323-0507-20 J2185 30 ML/1 GM 25/PK 63323-0508-30 J2185 MIACALCIN
2 ML MDV MYLAN INSTITUTIONAL 54766-0149-23 J0630MOZOBIL 20 MG/1.2
ML VIAL SANOFI AVENTIS 58468-0140-01 J2562NAFCILLIN** 1 GM
VIAL-10PK AURO MEDICS 55150-0122-15 S0032 2 GM VIAL-10PK
55150-0123-15 S0032 10 GM SDV 55150-0124-99 S0032OXACILLIN** 1 GM
VIAL-10PK AURO MEDICS 55150-0127-15 TBD 2 GM VIAL-10PK
55150-0128-24 TBD 10 GM SDV 55150-0129-99 TBDSIVEXTRO TEDIZOLID
PHOSPHATE 200 MG IV VIALS X 6 MERCK 67919-0041-02 P0300 200 MG IV
VIALS X 10 67919-0040-01 P0300 200 MG IV VIALS X 30 67919-0041-01
P0300 THROMBATE III 500 IU VIAL GRIFOLS 13533-0603-20 J7197TNKASE
50 MG VIAL GENENTECH 50242-0120-01 J3101ZERBAXA 1.5 GM/10-VL MERCK
67919-0030-01 J3490/C9452
Specialty Biopharmaceuticals and Pharmaceuticals
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
VIPc
VIPc
VIPcVIPc
VIPc
VIPc
VIPc
VIPc340B
VIPc340B
340B
VIPc Verified Inventory Program–Consignment eligible. Public
Health Services 340B pricing available.340B
14
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
Manufacturer NDC# Code*
O J9027
G 47335-0154-40 J9201O
47335-0047-40 J9263Z J9400 00024-5841-01 J9400Z J8999
O
50242-0085-27 J2997
J7196
42976-0121-02 J7196B J0597C J0840C J0878D J1162F 00052-0313-01
J3490 00052-0316-01 J3490 00052-0326-01 J3490F 23155-0521-42 J1940
23155-0521-44 J1940G S0132H J3490I J1327 00085-1177-01 J1327
00085-1177-02 J1327M 63323-0508-30 J2185
J2562
N 55150-0123-15 S0032 55150-0124-99 S0032O 55150-0128-24 TBD
55150-0129-99 TBDS 67919-0040-01 P0300 67919-0041-01 P0300 T
J7197T
MERCK 67919-0030-01 J
www.MyFluVaccine.com | biosupply.fffenterprises.com
V
P
*All codes should be verified between the provider and the
payer.
Generic Injectables Product Size Manufacturer NDC# Code*
GENERIC INJECTABLESCIDOFOVIR** 375 MG HERITAGE PHARMA
23155-0216-31 J0740ENOXAPARIN** 30 MG/0.3 ML TEVA PHARMA
00703-8530-23 J1650 60 MG/0.6 ML 00703-8560-23 J1650 80 MG/0.8 ML
00703-8680-23 J1650 120 MG/0.8 ML 00703-8610-23 J1650HYDRALAZINE**
20 MG/ML 25-PK FRESENIUS KABI 63323-0614-01 J0360LEVETIRACETAM**
500 MG/5 ML SUN PHARMA 62756-0513-44 TBD
PIPERACILLIN & TAZOBACTAM** 2.25 GM 10-PK FRESENIUS KABI
63323-0309-20 J2543 3.375 GM 10-PK 63323-0300-30 J2543 4.5 GM 10-PK
63323-0320-50 J2543PROCHLORPERAZINE EDISYLATE** 2 ML 10 MG VL 10-BX
HERITAGE PHARMA 23155-0294-42 TBDVANCOMYCIN** 10 GM 1-PK FRESENIUS
KABI 63323-0314-61 J3370 1 GM 10-PK 63323-0284-20 J3370 500 MG
25-PK 63323-0221-10 J3370 5 GM SDV 1-PK 63323-0295-61
J3370VASOPRESIN** 20 UNITS/ML FRESENIUS KABI 63323-0302-01
TBDVECURONIUM BROMIDE** 10 MG SUN PHARMA 47335-0391-44 TBD
ONCOLOGY (BIOSIMILARS)ZARXIO** 300 MCG/0.5 ML PFS SANDOZ
61314-0304-01 TBD 300 MCG/0.5 ML PFS 10-BX 61314-0304-10 TBD 480
MCG/0.8 ML PFS 61314-0312-01 TBD 480 MCG/0.8 ML PFS 10-BX
61314-0312-10 TBD
TO ORDER (800) 843-7477 | Fax (800) 418-4333 |
www.FFFenterprises.com | www.MyFluVaccine.com |
biosupply.fffenterprises.com
* All codes should be verified between the provider and the
payer. ** Call for eligibility through your GPO affiliation.
Surgical Sealants Product Size Manufacturer NDC# Code*
SURGICAL SEALANT GEL COSEAL 2 ML BAXTER BIOSCIENCE 01376-5404-61
— 4 ML 01376-5404-62 — 8 ML 01376-5404-63 —HEMOSTATIC MATRIX
FLOSEAL 5 ML BAXTER BIOSCIENCE 08541-2096-10 — 10 ML 08541-2096-12
—FIBRIN SEALANT TOPICAL TISSEEL VHSD KIT 2 ML BAXTER BIOSCIENCE
00944-4301-02 J3590/C9399 VHSD KIT 4 ML 00944-4302-04 J3590/C9399
VHSD KIT 10 ML 00944-4303-10 J3590/C9399 2 ML VHSD VALUPAK
00944-4201-03 J3590/C9399 4 ML VHSD VALUPAK 00944-4211-04
J3590/C9399 10 ML VHSD VALUPAK 00944-4212-10 J3590/C9399FIBRIN
SEALANT FROZENARTISS 2 ML BAXTER BIOSCIENCE 00944-8503-02 — 4 ML
00944-8503-04 — 10 ML 00944-8503-10 —TISSEEL 2 ML BAXTER BIOSCIENCE
00944-8402-02 — 4 ML 00944-8402-04 — 10 ML 00944-8402-10 —
Product Size Manufacturer NDC# Code*
Oncology (CONTINUED)
15
COAGUALATIONIM
MUNE
GLOBULINSHYPERIM
MUNES
INFLUENZA VACCINES& ANCILLARIES
OTHERVACCINES
ALBUMIN / PLASM
APROTEIN FRACTION
SPECIALTY& ONCOLOGY
GENERIC INJECTABLES& SURGICAL SEALANTS
http://www.fffenterprises.com/http://www.myfluvaccine.com/https://biosupply.fffenterprises.com/product-catalog
-
M
MissionHelping
n®g Healthcare Care
e serve.
life for the patients we
http://www.fffenterprises.com/
-
Experie
ence
Experie more than
We are proud of ou
ence n 100 million lives that we’ve protected.
ree years and ur 27 counterfeit-f
-
AMBIVIG . Formula ® ®
. ated to insPIre
Enabling More Days to Ld nts missed that PI patieewtal trial
shooPiv
deatrleoll teAM is wBIVIG
– s infuractions pe reseref adv oe ratThe6%7ns at 0.0actio
resereadv 1
–
ead a Normal Lifelr schook oorar of weys/yd 2.3 da 1
suiorf se oeat1% with a rd at 0.09elatn calcuen has beio
2
2
tep Ahead in IVIGA S *
Delivering Safety That Mattersalsnt seevid-erpeamT
AMBIVIG ®
2
1
https://biosupply.fffenterprises.com/bivigam-5gm-50ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigam
-
AM BIVIGUS plasm
wo Vial Sizes in T Two Vial Sizes
A fromM is manufactured in the US SA from ma for US providers
and patients.
ge, ced anadve aclud inr sculaag vellindw n
y occureath ma dl ae rentcud an action
isk of t rts atien paor Fe rsuble. Encticaae prt
ts at atien p viscosity in
vailable i AAvailable in T
730-6502-1NDC: 59
2
730-6503-1NDC: 5900 mL vialn contains a 1otA car
arning:WWarning: uline globnr with immuy occuombosis ma Thrs
ditionle conlabgucoayper immobilization, hgedolonproctisk far
rlascuavrdiod canviscosity aeryps, hertcatheo envatrn Iuline
Globnmmu of Itionaistrminwith the ad
g IGIVeceivints rtien paly ine common more occurilurfaismine,
adl failura ren, orctionnl dysfuenaosis, rombthrs ationistrdminore
aefts btien pa intionydrae htuadeqa
.or viscosityisk fr or cation f for comorm See full Prescribing
Inf form
Visit
. ences: 1erefR ®2.
com bivigam. to learn more today!
y s maorctisk faAM. Rding BIVIGclucts, inodu) prous (IGIVenvtra
inns, inogense of estrombosis, the ul threriatr aous oreny of vors,
a hist
ddosis, anhreptic ne, osmorilul faae rent, acuctionnysful daens.
Rorcysfunl daents. Rtien paosedisped prcts inodu) pr) (IGIVmanus
(Hu
ose. sucrintat conooes nAM dIGose. BIVcrg suinintacts conodu pr
V V pr rafusiond innded aecommenimum dose rt the minAM aIGer
BIVst
lood assess bdombosis anoms of thrt sympdns aor signor fits.
Monarning.ed wxe bo oxtple om
arn more today!
l.v Clin Immunoet RExperrt R
https://biosupply.fffenterprises.com/bivigam-5gm-50ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/bivigam-5gm-50ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/bivigam-10gm-100ml-human-ivig.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttp://www.biotestpharma.com/
-
BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] Rx
onlyBrief summary: Consult the full Prescribing Information for
complete product information WARNING: THROMBOSIS, RENAL
DYSFUNCTION, AND ACUTE RENAL FAILURE Thrombosis may occur with
immune globulin (IGIV) products, including BIVIGAM. Risk factors
may include: advanced age, prolonged immobilization,
hypercoagulable conditions, a history of venous or arterial
thrombosis, the use of estrogens, indwelling central vascular
catheters, hyperviscosity and cardiovascular risk factors.
Thrombosis may occur in the absence of known risk factors. Use of
Immune Globulin Intravenous (IGIV) products, particularly those
containing sucrose, has been reported to be associated with renal
dysfunction, acute renal failure, osmotic nephrosis, and death.
Patients at risk of acute renal failure include those with any
degree of pre-existing renal insufficiency, diabetes mellitus,
advanced age (above 65 years of age), volume depletion, sepsis,
paraproteinemia, or receiving known nephrotoxic drugs. Renal
dysfunction and acute renal failure occur more commonly in patients
receiving IGIV products containing sucrose. BIVIGAM does not
contain sucrose. For patients at risk of thrombosis, renal
dysfunction, or renal failure, administer BIVIGAM at the minimum
dose and infusion rate practicable. Ensure adequate hydration in
patients before administration. Monitor for signs and symptoms of
thrombosis and assess blood viscosity in patients at risk for
hyperviscosity.Indication and Usage: BIVIGAM is an Immune Globulin
Intravenous (Human), 10% Liquid, indicated for the treatment of
primary humoral immunodeficiency (PI). Contraindications: BIVIGAM
is contraindicated in patients who have had an anaphylactic or
severe systemic reaction to the administration of human immune
globulin. BIVIGAM is contraindicated in IgA deficiency patients
with antibodies to IgA and a history of hypersensitivity. Warnings
and Precautions: Thrombosis: Thrombosis may occur following
treatment with IGIV products, including BIVIGAM. Risk factors may
include: advanced age, prolonged immobilization, hypercoagulable
conditions, history of venous or arterial thrombosis, use of
estrogens, indwelling central vascular catheters, hyperviscosity
and cardiovascular risk factors. Thrombosis may occur in the
absence of known risk factors. Consider baseline assessment of
blood viscosity in patients at risk for hyperviscosity, including
those with cryoglobulins, fasting chylomicronemia/markedly high
triacylglycerols (triglycerides), or monoclonal gammopathies. For
patients at risk of thrombosis, administer BIVIGAM at the minimum
dose and infusion rate practicable. Ensure adequate hydration in
patients before administration. Monitor for signs and symptoms of
thrombosis and assess blood viscosity in patients at risk for
hyperviscosity. Hypersensitivity: Severe hypersensitivity reactions
may occur with IGIV products, including BIVIGAM. In case of
hypersensitivity, discontinue BIVIGAM infusion immediately and
institute appropriate treatment. Medications such as epinephrine
should be available for immediate treatment of acute
hypersensitivity reactions.
. Patients with known antibodies to IgA may have a greater risk
of developing potentially severe hypersensitivity and anaphylactic
reactions. BIVIGAM is contraindicated in IgA deficient patients
with antibodies against IgA and a history of hypersensitivity
reaction. Acute Renal Dysfunction and Acute Renal Failure: Acute
renal dysfunction/failure, osmotic nephrosis, and death may occur
upon use of human IGIV products. Ensure that patients are not
volume depleted before administering BIVIGAM. Periodic monitoring
of renal function and urine output is particularly important in
patients judged to be at increased risk of developing acute renal
failure. Assess renal function, including measurement of blood urea
nitrogen (BUN) and serum creatinine, before the initial infusion of
BIVIGAM and at appropriate intervals thereafter. If renal function
deteriorates, consider discontinuing BIVIGAM. In patients who are
at risk of developing renal dysfunction, because of pre-existing
renal insufficiency or predisposition to acute renal failure (such
as diabetes mellitus, hypovolemia, overweight, use of concomitant
nephrotoxic medicinal products or age of >65 years), administer
BIVIGAM at the minimum infusion rate practicable. Hyperproteinemia,
Increased Serum Viscosity, and Hyponatremia: Hyperproteinemia,
increased serum viscosity, and hyponatremia may occur in patients
receiving IGIV therapy, including BIVIGAM. It is critical to
clinically distinguish true hyponatremia from a pseudohyponatremia
that is associated with or causally related to hyperproteinemia
with concomitant decreased calculated serum osmolality or elevated
osmolar gap, because treatment aimed at decreasing serum free water
in patients with pseudohyponatremia may lead to volume depletion, a
further increase in serum viscosity, and a possible predisposition
to thrombotic events. Aseptic Meningitis Syndrome (AMS): AMS may
occur infrequently with IGIV treatments including BIVIGAM. AMS
usually begins within several hours to 2 days following IGIV
treatment. Discontinuation of IGIV treatment has resulted in
remission of AMS within several days without sequelae. AMS is
characterized by the following signs and symptoms: severe headache,
nuchal rigidity, drowsiness, fever, photophobia, painful eye
movements, nausea, and vomiting.Cerebrospinal fluid (CSF) studies
frequently reveal pleocytosis up to several thousand cells per
cubic millimeter, predominantly from the granulocytic series, and
elevated protein levels up to several hundred mg/dL, but negative
culture results. Conduct a thorough neurological examination on
patients exhibiting such signs and symptoms, including CSF studies,
to rule out other causes of meningitis. AMS may occur more
frequently in association with high doses (2 g/kg) and/or rapid
infusion of IGIV. Hemolysis: IGIV products, including BIVIGAM, may
contain blood group antibodies that can act as hemolysins and
induce in vivo coating of red blood cells (RBCs) with
immunoglobulin, causing a positive direct antiglobulin reaction
and, rarely, hemolysis. Delayed hemolytic anemia can develop
subsequent to IGIV therapy due to enhanced RBC sequestration,13 and
acute hemolysis, consistent with intravascular hemolysis, has been
reported. Monitor patients for clinical signs and symptoms of
hemolysis. If these are present after BIVIGAM infusion, perform
appropriate confirmatory laboratory testing. If transfusion is
indicated for patients who develop hemolysis with clinically
compromising anemia after receiving IGIV, perform adequate
cross-matching to avoid exacerbating on-going hemolysis.
Transfusion-Related Acute Lung Injury (TRALI): Noncardiogenic
pulmonary edema may occur in patients following IGIV treatment
including BIVIGAM. TRALI is characterized by severe respiratory
distress, pulmonary edema, hypoxemia, normal left ventricular
function, and fever. Symptoms typically appear within 1 to 6 hours
following treatment. Monitor patients for pulmonary adverse
reactions. If TRALI is suspected, perform appropriate tests for the
presence of anti- . TRALI may be managed using oxygen therapy with
adequate ventilatory support. Transmissible
Infectious Agents: Because BIVIGAM is made from human blood, it
may carry a risk of transmitting infectious agents, e.g., viruses,
and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No
cases of transmission of viral diseases or CJD have been associated
with the use of BIVIGAM. All infections suspected by a physician
possibly to have been transmitted by this product should be
reported by the physician or other healthcare provider to Biotest
Pharmaceuticals Corporation at 1-800-458-4244. Before prescribing
BIVIGAM, the physician should discuss the risks and benefits of its
use with the patient. Monitoring Laboratory Tests: Periodic
monitoring of renal function and urine output is particularly
important in patients judged to be at increased risk of developing
acute renal failure. Assess renal function, including measurement
of blood urea nitrogen (BUN) and serum creatinine, before the
initial infusion of BIVIGAM and at appropriate intervals
thereafter. Because of the potentially increased risk of thrombosis
with IGIV treatment, consider baseline assessment of blood
viscosity in patients at risk for hyperviscosity, including those
with cryoglobulins, fasting chylomicronemia/markedly high
triacylglycerols (triglycerides), or monoclonal gammopathies. If
signs and/or symptoms of hemolysis are present after an infusion of
BIVIGAM, perform appropriate laboratory testing for confirmation.
If TRALI is suspected, perform appropriate tests for the presence
of anti-neutrophil antibodies in both the
Interference with Laboratory Tests: After infusion of
immunoglobulin, the transitory rise of the various passively
transferred antibodies in the
sitive serological testing results, with the potential for
misleading interpretation. Passive transmission of antibodies to
erythrocyte antigens (e.g., A,
ADVERSE REACTIONS: Serious adverse reactions observed in
clinical trial subjects receiving BIVIGAM were vomiting and
dehydration in one subject. The most common
fatigue, infusion site reaction, nausea, sinusitis, blood
pressure increased, diarrhea, dizziness, and lethargy. Clinical
Trials Experience Because clinical trials are conducted under
widely varying conditions, adverse reaction rates observed in
clinical trials cannot be directly compared to rates in the
clinical trials of another product and may not reflect the rates
observed in clinical practice. In a multicenter, open-label,
non-randomized clinical trial, 63 subjects with PI, on regular IGIV
replacement therapy, received doses of BIVIGAM ranging from 254 to
1029 mg/kg (median dose 462.8 mg/kg) every 3 weeks or 4 weeks for
up to 12 months (mean 317.3 days; range 66 – 386 days). The use of
pre-medication was discouraged; however, if subjects required
pre-medication (antipyretic, antihistamine, or antiemetic agent)
for recurrent reactions to immune globulins, they were allowed to
continue those medications for this trial. Of the 746 infusions
administered, 41 (65%) subjects received premedication prior to 415
(56%) infusions. Fifty-nine subjects (94%) had an adverse reaction
at some time during the study. The proportion of subjects who had
at least one adverse reaction was the same for both the 3- and
4-week cycles. The most common adverse reactions observed in this
clinical trial were headache (32 subjects, 51%), sinusitis (24
subjects, 38%), fatigue (18 subjects, 29%), upper respiratory tract
infection (16 subjects, 25%), diarrhea (13 subjects, 21%), cough
(14 subjects, 22%), bronchitis (12 subjects, 19%), pyrexia (12
subjects, 19%), and nausea (9 subjects, 14%). Adverse reactions
(ARs) are those occurring during or within 72 hours after the end
of an infusion. In this study, the upper bound of the 1-sided 95%
confidence interval for the proportion of BIVIGAM infusions with
one or more temporally associated adverse reactions was 31%. The
total number of adverse reactions was 431 (a rate of 0.58 ARs per
infusion). Seven subjects (11.1%) experienced 11 serious ARs. Two
of these were related serious Table: Adverse Reactions (ARs)
(within 72 hours after the end of a BIVIGAM infusion) in
aSymptoms occurring under pre-existing fibromyalgia
ARs (vomiting and dehydration) that occurred in one subject. One
subject withdrew from the study due to ARs related to BIVIGAM
(lethargy, headache, tachycardia and pruritus). All 63
During the study, no subjects showed clinical evidence of
hemolytic anemia. No cases of transmission of viral diseases or CJD
have been associated with the use of BIVIGAM. During the clinical
trial no subjects tested positive for infection due to human
immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis
C virus (HCV). There was a single positive finding for parvovirus
(B19 virus) during the study. This subject came in contact with
acute B19 virus from working at a school greeting children where a
child was reported to have symptomatic Fifth's disease. There was
no cluster (no other cases in other subjects) of B19 virus
transmission with the IGIV batch concerned.DRUG INTERACTIONS Live
Virus Vaccines Immunoglobulin administration may transiently impair
the efficacy of live attenuated virus vaccines such as measles,
mumps, rubella, and varicella because the continued presence of
high levels of passively acquired antibody may interfere with an
active antibody response. The immunizing physician should be
informed of recent therapy with BIVIGAM so that appropriate
measures may be taken.
ARsNo. Subjects
Reporting ARs(% of Subjects)[n=63]
No. Infusions With ARs(% of Infusions)[n=746]
Headache 27 (43%) 115 (15.4%)Fatigue 15 (24%) 59 (7.9%)Infusion
Site Reaction 5 (8%) 5 (0.7%)Nausea 5 (8%) 8 (1.1%)Sinusitis 5 (8%)
5 (0.7%)Blood Pressure Increased 4 (6%) 5 (0.7%)Diarrhea 4 (6%) 4
(0.5%)Dizziness 4 (6%) 4 (0.5%)Lethargy 4 (6%) 4 (0.5%)Back Pain 3
(5%) 3 (0.4%)Blood Pressure Diastolic Decreased
3 (5%) 5 (0.7%)
Fibromyalgiaa 3 (5%) 17 (2.3%)Migraine 3 (5%) 8 (1.1%)Myalgia 3
(5%) 4 (0.5%)Pharyngolaryngeal Pain 3 (5%) 3 (0.4%)
Dec-2013, [10760-90-IGG-032013_R01]
-
Th
roduPe
ucts you
eed n
d
yowhen
eednu o
d them.
Fl V
Hype
Coag
Imm
Flu V
i V
esunerimm
gulation Products
e Globulinsunm
eaccin V Vaccin
Spec
Othe
Albumin
Hype
cialty Biologicals
andes acciner V
umin
esunerimm
Inc©2015 FFF Enterprises, . ente.FFFwww(800
erprises.com) 843-7477
https://biosupply.fffenterprises.com/product-cataloghttp://www.fffenterprises.com
-
f
R o
Visit NovoeightPro.com today to learn more.
N
a h
T
T
f
S
6
Indications and UsageNovoeight® (Antihemophilic Factor
[Recombinant]) is indicated for use in adults and children with
hemophilia A for control and prevention of bleeding, perioperative
management, and routine prophylaxis to prevent or reduce the
frequency of bleeding episodes.
Novoeight® is not indicated for the treatment of von Willebrand
disease.
Important Safety InformationDo not use in patients who have had
life-threatening hypersensitivity reactions, including anaphylaxis,
to Novoeight® or its components, including hamster proteins.
Anaphylaxis and severe hypersensitivity reactions are possible.
Patients may develop hypersensitivity to hamster proteins, which
are present in trace amounts in the product. Should symptoms occur,
discontinue Novoeight® and administer appropriate treatment.
Development of activity-neutralizing antibodies (inhibitors) may
occur. If expected plasma factor VIII activity levels are not
attained, or if bleeding is not controlled with an appropriate
dose, perform an assay that measures factor VIII inhibitor
concentration.
The most frequently reported adverse reactions (≥0.5%) were
injection site reactions, increased hepatic enzymes, and
pyrexia.
1
FFF Enterprises •
All rights reserved. 0315-00026032-1 April 2015
https://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttp://www.novoeightpro.com/
-
Multiple dose strengths help infuse patients with fewer
vials1
Novoeight® — a proven safe and effective treatment for hospital
patients with hemophilia A1
Indicated for use in adults and children with hemophilia A
for:
• Control and prevention of bleeding
• Perioperative management
• Routine prophylaxis to prevent or reduce the frequency of
bleeding episodes
Novoeight® (Antihemophilic Factor [Recombinant]) — an evolution
in treatment for hospital patients with hemophilia A
Please see Prescribing Information for complete storage
instructions.
36˚F to 46˚F
30
6
USABILITY
FLEXIBILITY
STORAGE
VALUE
UP TO MONTHS
refrigerated storage1
VIAL SIZESRoom temperature storage
FOR 12 MONTHS
UP TO 86 FO after reconstitution1
• Longest of all recombinant factor VIII products1-7
4-HOUR STORAGE TIME
Please see Brief Summary of Prescribing Information on the
adjacent page.
References: 1. Novoeight® [package insert]. Plainsboro, NJ: Novo
Nordisk Inc.; 2014. 2. ADVATE™ [package insert]. Westlake Village,
CA: Baxter Healthcare Corp.; 2014. 3. ELOCTATE® [package insert].
Cambridge, MA: Biogen Idec Inc.; 2014. 4. Helixate® FS [package
insert]. Whippany, NJ: Bayer HealthCare LLC; 2014. 5. Kogenate® FS
[package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2014. 6.
RECOMBINATE™ [package insert]. Westlake Village, CA: Baxter
Healthcare Corp.; 2014. 7. XYNTHA® [package insert]. Philadelphia,
PA: Wyeth Pharmaceuticals Inc., 2014.
I
a
i
1Facilitates quick reconstitution and consistent preparation of
treatment
SYRINGE4 mL pre-�lled diluent
Talk to your authorized distributor to learn more about
Novoeight® or visit NovoeightPro.com for answers and resources. FFF
Enterprises • 1-800-843-7477
© 2015 Novo Nordisk All rights reserved. 0315-00026032-1 April
2015
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New
Jersey 08536 U.S.A.
Novoeight® is a registered trademark of Novo Nordisk Health Care
AG.
1 9 2:12 PM
https://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/catalogsearch/result/?q=novoeight?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttps://biosupply.fffenterprises.com/catalogsearch/result/?q=novoeight?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigamhttp://www.novoeightpro.com/https://biosupply.fffenterprises.com/novoeight-250-unit.html?utm_source=BSTQ_2015-10&utm_medium=AD&utm_campaign=Prod&utm_term=Bivigam
-
Novoeight®, Antihemophilic Factor (Recombinant)
Rx Only
BRIEF SUMMARY: Please consult package insert for full
prescribing information
INDICATIONS AND USAGE: Novoeight®, Antihemophilic Factor
(Recombinant), is indicated for use in adults and children with
hemophilia A (congenital factor VIII de�ciency or classic
hemophilia) for: control and prevention of bleeding episodes;
Perioperative management; routine prophylaxis to prevent or reduce
the frequency of bleeding episodes. Novoeight® is not indicated for
the treatment of von Willebrand disease.
CONTRAINDICATIONS: Do not use in patients who have had
life-threatening hypersensitivity reactions, including anaphylaxis,
to Novoeight® or its components (including traces of hamster
proteins).
WARNINGS AND PRECAUTIONS: Hypersensitivity Reactions:
Hypersensitivity reactions, including anaphylaxis, are possible
with Novoeight®. Novoeight® contains trace amounts of hamster
proteins. Patients treated with this product may develop
hypersensitivity to these non-human mammalian proteins. Early signs
of hypersensitivity reactions that can progress to anaphylaxis
include angioedema, chest tightness, dyspnea, wheezing, urticaria,
and pruritus. Immediately discontinue administration and initiate
appropriate treatment if allergic- or anaphylactic-type reactions
occur. Neutralizing Antibodies: Formation of neutralizing
antibodies (inhibitors) to factor VIII can occur following
administration of Novoeight®. Monitor all patients for the
development of inhibitors by appropriate clinical observation and
laboratory testing. If the expected plasma levels of factor VIII
activity are not attained, or if bleeding is not controlled with an
appropriate dose, perform testing for factor VIII inhibitors.
Monitoring Laboratory Tests: Monitor plasma factor VIII activity
levels by the one-stage clotting assay or the chromogenic substrate
assay to con�rm that adequate factor VIII levels have been achieved
and maintained, when clinically indicated. Perform assay to
determine if factor VIII inhibitor is present if expected plasma
factor VIII activity levels are not attained, or if bleeding is not
controlled with the expected dose of Novoeight®. Determine
inhibitor levels in Bethesda Units.
ADVERSE REACTIONS: The most frequently reported adverse
reactions (≥ 0.5%) were injection site reactions, increased hepatic
enzymes, and pyrexia. Clinical Trials Experience: Because clinical
trials are conducted under widely varying conditions, adverse
reaction rates observed in the clinical trials of a drug cannot be
directly compared to rates in clinical trials of another drug and
may not re�ect the rates observed in clinical practice. During the
clinical development of Novoeight®, 214 male previously treated
patients (PTPs; exposed to a factor VIII-containing product for
≥150 days) with severe hemophilia A (factor VIII level ≤1%)
received at least one dose of Novoeight® as part of either routine
prophylaxis, on-demand treatment of bleeding episodes,
perioperative
management of major and minor surgical, dental, or other
invasive procedures, or pharmacokinetic evaluation of Novoeight®.
Thirty-one subjects (14%) were
-
distributes evious st pr
passive RF erified Inv V
s – leaving you ee to focus i
fr torage location n and conditi
a FID technology y to track, tra g ogr Consig –ram ventory
Pr
e. s on patient carod e pr ion of the critical-car
ace, and verify the moment of use, statuses gnment (VIPc)™
ducts FFF t of use,
e-of-the-art,
Eliminahighhi h va
Increase
high-va
tlue critical productsoducts
ces carrying cl i i l
osts ofd
es visibility of pro oduct
lue critical pr
Monit,
ors remotely priquantityquantity l, loca, loca i dtion andtion
and
temperature
r d
oduct d
iseprert©2015 FFF En
(800) 84 .nc, Ies
43-7477 x1142 | [email protected]
[email protected]
http://www.fffenterprises.com/services/verified-inventory-program.htmlhttp://www.fffenterprises.com/services/verified-inventory-program.htmlmailto:[email protected]
-
ount on FFF's securC»Y DELIVER AFELY WE S
om Choose fr»ANTITY OU PICK THE QUY
en vonC»TE AT Y DOU PICK THE DELIVERY
egeed Channel Intante supply channel with Guar ecur
oductsolio of proad portf a br
)se(tery dat delivOUR bese Yniently secur
grity™
O U P Y
O ORDER T
O U T E • YA I C K T H E D
7747.843.om | 800c.cineac | MyFluV
A P R O G R A M O F F F F E N T E R P R I S E S
A N T I T Y • W E D E L I V E R P I C K T H E Q U
v 0515e7 Rerprises, Inc. FL3315 FFF Ent©20
http://www.myfluvaccine.com/Login.aspxhttp://www.myfluvaccine.com/
-
AEAHGNNINALP
SIDA
RPOWEPSUR OUYAEAHGNNINALP
OPTECINCAVULFRUOYESCHOO
. REWSIDA
:NTIO
tion.cInje
.lasanaIntr
-.ladermaIntr
.
j
||
http://www.myfluvaccine.com/http://www.myfluvaccine.com/http://www.myfluvaccine.com/
-
28 FL21
5 101
5
h24h
enterprises.com .FFF(800) 843-7477 | www